UroGen Pharma (URGN) Non Operating Income (2018 - 2023)
UroGen Pharma's (URGN) quarterly Non Operating Income came in at $71000.0 in Q3 2023, up 91.89% YoY from $37000.0 in Q3 2022, and up 336.67% on a QoQ basis from -$30000.0 in Q2 2023.
UroGen Pharma (URGN) Non Operating Income (2018 - 2023) Analysis & Trends
UroGen Pharma (URGN) has 5 years of Non Operating Income data on file, last reported at $71000.0 in Q3 2023.
- Quarterly Non Operating Income rose 91.89% year-over-year to $71000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was -$37000.0 (down 163.79% YoY) and the FY2022 annual result came in at $72000.0, up 147.06% from the prior year.
- Non Operating Income climbed to $71000.0 in Q3 2023, from -$30000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $989000.0 in Q1 2019 to a low of -$239000.0 in Q2 2021.
- A 4-year average of $77833.3 and a median of -$9500.0 in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income jumped 331.25% — and 2023, when it sank 275.0%.
- Tracing URGN's Non Operating Income over 4 years: stood at $989000.0 in 2019, then plunged by 107.79% to -$77000.0 in 2021, then grew by 18.18% to -$63000.0 in 2022, then soared by 212.7% to $71000.0 in 2023.
- The last three Non Operating Income figures came in at $71000.0 (Q3 2023), -$30000.0 (Q2 2023), and -$15000.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 71,000.00 |
| Jun 30, 2023 | -30,000.00 |
| Mar 31, 2023 | -15,000.00 |
| Dec 31, 2022 | -63,000.00 |
| Sep 30, 2022 | 37,000.00 |
| Jun 30, 2022 | 102,000.00 |
| Mar 31, 2022 | -4,000.00 |
| Dec 31, 2021 | -77,000.00 |
| Sep 30, 2021 | -16,000.00 |
| Jun 30, 2021 | -239,000.00 |
| Mar 31, 2021 | 179,000.00 |
| Mar 31, 2019 | 989,000.00 |
| Mar 31, 2018 | 258,000.00 |